Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor

Annals of Surgical Oncology

Volumn 14, Issue 7, 2007, Pages 2018-2027

  Rutkowski, Piotr ^a   Nowecki, Zbigniew I ^a   Michej, Wanda ^a   Dębiec Rychter, Maria ^b   Woźniak, Agnieszka ^c   Limon, Janusz ^c   Siedlecki, Janusz ^a   Grzesiakowska, Urszula ^a   Kąkol, Michał ^d   Osuch, Czesław ^e   Polkowski, Marcin ^a   Głuszek, Stanisław ^f   Żurawski, Zbigniew ^a   Ruka, Włodzimierz ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d Regional Oncological Center   (Poland)

^e JAGIELLONIAN UNIVERSITY   (Poland)

^f City Hospital   (Poland)

Author keywords

Gastrointestinal stromal tumor; Prognosis; Surgery

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURGERY; DISEASE FREE SURVIVAL; EPITHELIOID CELL; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK ASSESSMENT; SCHOOL CHILD; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TUMOR RECURRENCE; TUMOR VOLUME; UNIVARIATE ANALYSIS;

EID: 34250821693     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9377-9     Document Type: Article

References (45)

1. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kinblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristic of the interstitial cell of Cajal. Am J Pathol 1998; 152:1259-69
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1-12
3. Trent JC, Benjamin RS. New developments in gastrointestinal stromal tumor. Curr Opin Oncol 2006; 18:386-95
4. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33:459-65
5. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002; 38(Suppl 5):S39-51
6. Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal tumors: a review. Hum Pathol 2002; 33:478-83
7. Eisenberg BL, Judson I. Surgery, imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004; 11:465-75
8. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in pre-imatinib mesylate era. Cancer 2005; 103:821-9
9. Debiec-Rychter M, Dumez H, et al. EORTC Soft Tissue and Bone Sarcoma Group. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40:689-95
10. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: J Wiley and Sons, 1999
11. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51-8
12. Kim CJ, Day S, Yeh KA. Gastrointestinal stromal tumors: analysis of clinical and pathologic factors. Am Surg 2001; 67:135-7
13. Hinz S, Pauser U, Egberts JH, Schafmayer C, Tepel J, Fandrich F. Audit of a series of 40 gastrointestinal stromal tumour cases. Eur J Surg Oncol 2006; 32:1125-9
14. Pierie JP, Choudry U, Muzikansky A, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001; 136:383-9
15. Ng E, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Ann Surg 1992; 215:68-77
16. Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006; 202:623-9
17. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-80
18. Bucher P, Egger JF, Gervaz P, et al. An audit of surgical management of gastrointestinal stromal tumours (GIST). Eur J Surg Oncol 2006; 32:310-4
19. Clary BM, Dematteo RP, Lewis JJ, et al. Gastrointestinal stromal tumors and leiomyosarcomas of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 2001; 8:290-99
20. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8:50-9
21. Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus. A clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001; 25:1121-33
22. Aparicio T, Boige V, Sabourin JC, et al. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol.2004; 30:1098-103
23. Bucher P, Taylor S, Villiger P, Morel P, Brundler MA. Are there any prognostic factors for small intestinal stromal tumors? Am J Surg 2004; 187:761-6
24. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29:52-68
25. Miettinen M, Kopczynski J, Makhlouf HR, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol.2003; 27:625-41
26. Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006; 30:477-89
27. Kindblom LG, Meis KindBlom J, Bumming P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal tumors (GIST): a population based study of 600 cases. Ann Oncol 2003; 13:157
28. Buemming P, Meis-Kindblom JM, Kindblom LG, et al. Is there an indication for adjuvant treatment with imatinib mesylate in patients with aggressive gastrointestinal stromal tumors (GISTs)? (abstract 3289). Proc Am Soc Clin Oncol 2003; 22:818
29. Bumming P, Ahlman H, Andersson J, Meis-Kindblom JM, Kindblom LG, Nilsson B. Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours. Br J Surg 2006; 93:836-43
30. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23:82-7
31. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20:3898-905
32. Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003; 6:39-48
33. Ueyama T, Guo KJ, Hashimoto H, et al. A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer 1992; 69:947-55
34. Andersson J, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 2006; 130:1573-81
35. Kim TW, Lee H, Kang YK, et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004; 10:3076-81
36. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59:4297-300
37. Corless CL, McGreevey L, Haley A, Twon A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002; 160:1567-72
38. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22:3813-25
39. Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Sem Diagn Pathol 2006; 23:91-102
40. Carillo R, Candia A, Rodriguez-Peralto JL, Caz V. Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol 1997; 28:160-5
41. Ozguc H, Yilmazlar T, Yerci O, et al. Analysis of prognostic and immunohistochemical factors in gastrointestinal stromal tumors with malignant potential. J Gastrointest Surg 2005; 9:418-29
42. Cunningham RE, Federspiel BH, McCarthy WF, Sobin LH, O'Leary TJ. Predicting prognosis of gastrointestinal smooth muscle tumors. Role of clinical and histologic evaluation, flow cytometry, and image cytometry. Am J Surg Pathol 1993; 17:588-94
43. Liu FY, Qi JP, Xu FL, Wu AP. Clinicopathological and immunohistochemical analysis of gastrointestinal stromal tumor. World J Gastroenterol 2006; 12:4161-5
44. Hu TH, Chuah SK, Lin JW, et al. Expression and prognostic role of molecular markers in 99 KIT-positive gastric stromal tumors in Taiwanese. World J Gastroenterol 2006; 12:595-602
45. Wong NA, Young R, Malcomson RD, et al. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003; 43:118-26